Innovotech Reports 44% Revenue Drop in Q1 2026 as Large Project Slows, Accelerates Strategic Shift
Innovotech's Q1 revenue fell 44% due to reduced activity from a major customer, prompting the company to accelerate diversification and cost-reduction efforts.
Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported a sharp decline in first-quarter financial results on Tuesday, with revenue falling 44% year-over-year to $648,140 for the three months ended March 31, 2026. The life sciences services and technology company attributed the drop almost entirely to a change in activities for a large project with a major customer that had been expected to continue through the year.
Gross profit for the quarter was $202,231, yielding a gross margin of 31.2%, down from 53.6% in the same period last year. The company said margins were negatively impacted by underutilized capacity, as it maintained staffing and operational readiness in anticipation of executing the planned customer work. The net loss for the quarter was $401,295, compared to net income of $63,523 in Q1 2025.
Operating expenses increased year-over-year, reflecting the integration of Keystone Labs and Innovotech Labs in Q1, the relocation of the former Keystone Labs operations to a new facility, and investments in a stronger sales organization. The company, which specializes in applied microbiology, analytical chemistry, and regulated laboratory services, continues to advance its strategic transformation, including strengthening its leadership and commercial teams and completing its OTCQB listing in the U.S.
“Management remains committed to investing in a more diversified, resilient, and scalable platform,” said Innovotech CEO Craig Milne. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The results underscore the risks of customer concentration, a challenge Innovotech is actively addressing. The company operates with a strong liquidity position and maintains a meaningful equity base, providing flexibility to manage near-term volatility while continuing to execute its longer-term strategy. Management noted it is expanding service offerings and capabilities to generate consistent recurring revenue and mitigate such client concentration risk.
Innovotech is a recognized leader in biofilm science and antimicrobial testing, providing advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. The company operates through ISO-certified and GMP-accredited laboratories and supports clients across multiple sectors and geographies. Its proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing.
The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. For more information about Innovotech, visit https://www.innovotech.ca.
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.